Off-label GLP-1 agonist treatment in 43 non-diabetic patients: Are weight loss and treatment tolerance equally promising outside of clinical trials?

Context: Recent data from controlled clinical trials have demonstrated that GLP-1 agonists are a well-tolerated therapy-option for weight loss in obese patients without type 2 diabetes mellitus. Objective: To investigate whether continuation of treatment, side-effects and effect on weight loss of GLP-1 agonists are equally promising in dairy clinical practice settings in non-diabetics. Methods: Obese, non-diabetic patients of our interdisciplinary obesity centre were treated off-label with glp-1 agonists. Application was started low dose and increased if side effects were tolerable. Monthly costs were 125 Euros…